

Summary of Re-audit Follow-Up Results

Below is a summary of a follow-up on sustainability requirements for a supplier to Sweden's regions. The summary reflects the results of the audit as well as activities carried out as a result. It has been updated continuously as new activities related to the follow-up have been conducted, until all potential non-conformities have been addressed and the follow-up is considered complete. For questions regarding the summary, please contact the Regional Office for Sustainable Procurement.

www.hallbarupphandling.se

Log

Last updated

2026-02-19

General Information

Supplier	Betapharm Arzneimittel GmbH
Regions with Agreement	Region Jönköpings län, Region Östergötland and Region Kalmar län
Risk Area	Pharmaceutical
Product	Antibiotics
Type of Follow-Up	Digital audit
Requirement	Sustainable supply chains
Re-audit Date	2025-09-24
For more information	Jenny Forsell Skoog, Västra Götalandsregionen

Re-audit Results

Summary of the Re-audit	Betapharm was open and transparent throughout the audit and has made significant progress since the previous review. A substantial amount of work has been carried out, and the supplier is clearly on the right track. The updated Code of Conduct has been implemented and cascaded throughout the supply chain, with several suppliers already having signed. A framework for risk analysis has been established with the support of [REDACTED] and external consultants, identifying high-risk products and providing a structured basis for prioritization.	
	At the same time, two non-conformities were identified: the lack of a risk-based monitoring system and the absence of structured deviation management. Continued efforts are therefore needed to further integrate risk-based follow-up and corrective action processes into daily operations.	
Audit Results	Sustainable Supply Chains	Assessment*
	1. Forwarding of commitment	
	2. Risk Assessment	
	3. Follow-Up	
	4. Non-Conformance Management	
	Explanations	
	Non-Conformance	
	No identified non-conformities	
	*For a detailed description, see Appendix 1. Non-Conformities	
Next Actions	A new follow-up audit has been scheduled for 2026-05-19.	

Appendix 1 - Non-Conformities

Sustainable Supply Chains	
Non-Conformity	Follow-up/Monotoring - Betapharm has not yet established a risk-based system for monitoring suppliers and subcontractors.
Supplier's Action	As per suppliers' obligation, our third party code of conduct was revised after the last audit conducted in December-2024 it includes clear mentioning about UN Universal Declaration on Human Rights, ILO conventions-covering forced or compulsory labour, child labour, discrimination, as well as freedom of association, etc. Currently, [REDACTED] accepted our revised code of conduct and this will be completed for rest of the suppliers in the [REDACTED] We have mapped and shown entire supply chain of [REDACTED] in the previous audit. In the supply chain, risks are identified using an online tool (Currently [REDACTED]) and [REDACTED] framework for assessment. Based on [REDACTED] framework, all components of supply chain are grouped into high, medium, or low risk categories. This Assessment has been shown for [REDACTED] already. This will be extended to all products in Nordics & then Europe in a phased manner. We will be implementing an ESG project management tool and the [REDACTED] alerts will be captured in this tool on a [REDACTED] Other sources of ESG information on vendors will be reported in the tool, which include but not limited to desktop audits, onsite audits, [REDACTED] (as per availability). All alerts will be classified as per severity and communicated to category leads/ ESG lead for necessary action. The responses received by category leads/ ESG Lead from vendors will be captured into this tool within [REDACTED] of the alert being shared with the supplier. Any exceptional alert with high severity to be taken as soon as received from [REDACTED] and response must be recorded within [REDACTED] days. All these activities will be led by ESG lead and monitored by ESG Risk Committee (ERC) comprising of Director level and above representatives from Commercial Organization, ESG Organization and Global Procurement. Follow-up actions are based on the risk category. High-risk suppliers to be audited [REDACTED] to be done as per requirements. High-risk suppliers for [REDACTED] will be audited [REDACTED] Medium risk supplier to be reviewed [REDACTED] and low-risk suppliers to be reviewed every [REDACTED] and rest of the methodology to be same as high-risk suppliers. Severity matrix which has been defined along with [REDACTED] will be used to define the severity for all products in Nordics and subsequently Europe. For [REDACTED] we have already shown the entire risk matrix with the severity during the September audit. Any non-compliance or gaps identified will be addressed through a corrective and preventive action plan, which includes setting timelines, assigning responsibilities,

	and tracking resolution progress to ensure continuous improvement and alignment with our requirements.
Timeline	Risk assessment for
Non-Conformity	Non-Conformance Management - Betapharm lacks a structured system for documenting and following up on deviations.
Supplier's Action	We currently lack a structured system to document and follow up on deviations. To address this, we plan to introduce an ESG project management tool that supports a standardized workflow for tracking deviations and managing corrective and preventive actions (CAPA). Any non-compliance or gaps identified will be addressed through a corrective and preventive action plan, which includes setting timelines, assigning responsibilities, and tracking resolution progress to ensure continuous improvement and alignment with our requirements. All alerts to be classified as per severity and will be communicated to category leads/ ESG lead for necessary actions. The leads/ ESG lead of the alert being shared with the supplier. Any exceptional alert with high severity to be taken as soon as received from the tool and response has to be recorded Progress on deviation management will be reviewed in a quarterly steering committee meeting chaired by Procurement, Human resource and ESG Vice Presidents. Minutes of meeting and the action items emanating from the meeting will be captured in the ESG project management tool. In case of non-conformity to the CAPA within the agreed timelines, vendor will be given intimation to complete the CAPA within additional timeline In case of continued non-conformity, we will initiate alternative vendor search, qualify the new vendor and move our supplies to the new vendor as per regulatory timelines for the approval of vendor. All the action plans ESG management process shared above will be part of an official ESG Management Guideline within the organisation and shared with all related parties within next 3 months.
Timeline	The table below outlines a tentative stage-wise timeline for Tool implementation:

